Blog

  • Zombie ideas

    Paul Krugman, the Nobel Prize-winning economist, recently wrote a column about a zombie idea, which he defines as “an idea that should have been killed by evidence, but refuses to die.” I would argue that we have zombie ideas in the omega-3 space as well. The most prevalent is the recent deluge of studies from cardiologists and doctors that purport to show omega-3s are not beneficial for cardiovascular disease. Perhaps EPA and DHA are maligned because of their association with the broader dietary supplement industry, which is not trusted by doctors or consumers, but that should not blind res...

  • How can we combat “omega-3 fatigue” in the media?

    GOED’s recently-commissioned meta analysis linking omega-3 intake to a reduction in blood pressure was very exciting for us and for our members. Lead author Dominik Alexander, principal epidemiologist at Exponent, said that it’s rare to see such a large body of research (70 studies) with such a consistent result. Additionally, the message that consuming omega-3s can help reduce blood pressure as much as other common lifestyle changes like reducing sodium or alcohol intake and increasing physical activity is an easy one for consumers to understand. Yet the media has not been overly inte...

  • Is the time for eye health coming?

    Back in 2010, I remember sitting at a conference listening to Dr. Jeffrey Anshel from the Ocular Nutrition Society talk about the benefits of omega-3s in eye health. The gist of the talk was that omega-3s are an important part of the eye, which is something most ophthalmologists have recognized for years.  However, this position had been developed without any human clinical trials having been published to date. So why exactly is that? It really boils down to two factors. First, omega-3s have been shown to help a variety of eye health maladies in multiple animal and in-vitro studies. Se...

  • Dr. Jay Udani, SELECT investigator, comments on prostate cancer study

    In GOED’s continuing response to the recent study linking omega-3s to prostate cancer risk, we recently interviewed Dr. Jay Udani, CEO and founder of Medicus Research, and an investigator on the original SELECT study upon which this paper was based. Dr. Udani shares his unique perspective and corroborates the many criticisms of the study. See what he had to say:  

  • Omega-3s and prostate cancer risk

    Omega-3s and Prostate Cancer Risk Review of: “Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial” Theodore M. Brasky, Amy K. Darke, Xiaoling Song, Catherine M. Tangen, Phyllis J. Goodman, Ian M. Thompson, Frank L. Meyskens Jr, Gary E. Goodman, Lori M. Minasian, Howard L. Parnes, Eric A. Klein, Alan R. Kristal Published ahead of print in Journal of the National Cancer Institute, July 10, 2013. As many of you know, a study was published earlier this week linking omega-3s to an increased risk of prostate cancer. GOED has revi...

  • John Carlson

    John Carlson was considered a pioneer that helped build the natural products industry. As a co-founder of Carlson Labs, he was integral in supplying high quality vitamins and minerals for over 45 years. Carlson was one of the first companies to understand the important health benefits of omega-3’s contained in fish oils and introduce them to the North American market in 1982.

  • U.S. Joint Chiefs Says Omega 3s Could Improve Force Fitness

    GOED said, ...'the specific mention of omega 3s means the U.S. military is giving serious thought to the role they can play in soldiers' health

  • Lovaza Battles Supplements for Slice of Omega-3 Market

    These ads have been good for business [by] bringing awareness to the whole category," [said Adam Ismail, Executive Director of GOED]

  • Bruce Miller

    Bruce A. Miller helped found Marine Ingredients, one of the founding GOED members and a pioneer in the omega-3 industry, in 1982. Miller helped build Marine Ingredients to become a respected leader in the industry and – before his untimely death in 2017 – was Executive Vice President of the company.